Chase Science Co., Ltd (SHE:300941)
China · Delayed Price · Currency is CNY 13.89
-0.25 (-1.77%)
At close: Nov 13, 2026
Chase Science Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 244.82 | 246.62 | 209.36 | 261.25 | 395.16 | 420.37 | |
Revenue Growth | 6.32% | 17.80% | -19.86% | -33.89% | -6.00% | -31.52% |
Cost of Revenue | 148.29 | 154.47 | 103.65 | 118.54 | 218.73 | 246.31 |
Gross Profit | 96.53 | 92.15 | 105.71 | 142.7 | 176.43 | 174.06 |
Selling, General & Admin | 62.01 | 48.26 | 55.25 | 47.12 | 40.55 | 39.36 |
Research & Development | 44.01 | 34.39 | 40.83 | 53.69 | 51.32 | 43.99 |
Other Operating Expenses | 0.43 | -0.24 | -1.32 | -2.93 | -4.71 | -4.96 |
Operating Expenses | 107.61 | 85.48 | 92.5 | 93.3 | 93.92 | 88.4 |
Operating Income | -11.07 | 6.66 | 13.21 | 49.4 | 82.51 | 85.66 |
Interest Expense | - | -0.12 | -0.23 | -0.23 | -0.26 | -0.22 |
Interest & Investment Income | 17.91 | 25.81 | 35.13 | 36.27 | 34.19 | 28.41 |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.03 | 0.03 | 0.14 | -0.04 |
Other Non Operating Income (Expenses) | -2.59 | -0.75 | -0.44 | -0.09 | -0.13 | -0.17 |
EBT Excluding Unusual Items | 4.2 | 31.56 | 47.69 | 85.38 | 116.45 | 113.64 |
Impairment of Goodwill | -3.33 | -3.33 | - | - | - | - |
Gain (Loss) on Sale of Investments | 6.02 | 1.92 | 0 | 0.13 | 0.1 | 0.22 |
Gain (Loss) on Sale of Assets | -0.03 | -0 | 0.06 | -0 | - | -0 |
Asset Writedown | -0.41 | 7.46 | 7.65 | 2.19 | -0 | - |
Other Unusual Items | 1.06 | 1.06 | 0.72 | 2.07 | 3.87 | 4.06 |
Pretax Income | 7.51 | 38.67 | 56.13 | 89.76 | 120.41 | 117.92 |
Income Tax Expense | 2.58 | 4.62 | 1.01 | 8.06 | 9.91 | 11.89 |
Earnings From Continuing Operations | 4.93 | 34.05 | 55.11 | 81.7 | 110.5 | 106.03 |
Minority Interest in Earnings | 1.28 | -1.29 | 0.49 | -0.43 | 0.02 | - |
Net Income | 6.21 | 32.76 | 55.61 | 81.27 | 110.52 | 106.03 |
Net Income to Common | 6.21 | 32.76 | 55.61 | 81.27 | 110.52 | 106.03 |
Net Income Growth | -85.44% | -41.08% | -31.57% | -26.47% | 4.24% | -27.56% |
Shares Outstanding (Basic) | 213 | 205 | 206 | 203 | 205 | 204 |
Shares Outstanding (Diluted) | 213 | 205 | 206 | 203 | 205 | 204 |
Shares Change | 7.74% | -0.57% | 1.37% | -0.74% | 0.38% | 32.78% |
EPS (Basic) | 0.03 | 0.16 | 0.27 | 0.40 | 0.54 | 0.52 |
EPS (Diluted) | 0.03 | 0.16 | 0.27 | 0.40 | 0.54 | 0.52 |
EPS Growth | -86.48% | -40.74% | -32.50% | -25.93% | 3.85% | -45.44% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 56.5 | -24 | 14.79 | -2.01 | 88.63 | 101.03 |
Free Cash Flow Per Share | 0.27 | -0.12 | 0.07 | -0.01 | 0.43 | 0.49 |
Dividend Per Share | 0.075 | 0.082 | 0.140 | 0.140 | 0.170 | 0.153 |
Dividend Growth | -40.95% | -41.43% | 0% | -17.65% | 10.89% | -23.35% |
Gross Margin | 39.43% | 37.36% | 50.49% | 54.62% | 44.65% | 41.41% |
Operating Margin | -4.52% | 2.70% | 6.31% | 18.91% | 20.88% | 20.38% |
Profit Margin | 2.54% | 13.29% | 26.56% | 31.11% | 27.97% | 25.22% |
Free Cash Flow Margin | 23.08% | -9.73% | 7.07% | -0.77% | 22.43% | 24.03% |
EBITDA | -9.89 | 7.55 | 13.71 | 50.07 | 83.18 | 86.47 |
EBITDA Margin | -4.04% | 3.06% | 6.55% | 19.17% | 21.05% | 20.57% |
D&A For EBITDA | 1.18 | 0.89 | 0.51 | 0.67 | 0.67 | 0.82 |
EBIT | -11.07 | 6.66 | 13.21 | 49.4 | 82.51 | 85.66 |
EBIT Margin | -4.52% | 2.70% | 6.31% | 18.91% | 20.88% | 20.38% |
Effective Tax Rate | 34.37% | 11.95% | 1.80% | 8.98% | 8.23% | 10.09% |
Revenue as Reported | 90.35 | 246.62 | 209.36 | 261.25 | 395.16 | 420.37 |